Historical Valuation
Amylyx Pharmaceuticals Inc (AMLX) is now in the Fair zone, suggesting that its current forward PS ratio of 12059.03 is considered Fairly compared with the five-year average of 0.79. The fair price of Amylyx Pharmaceuticals Inc (AMLX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：11.57
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Amylyx Pharmaceuticals Inc (AMLX) has a current Price-to-Book (P/B) ratio of 3.78. Compared to its 3-year average P/B ratio of 2.93 , the current P/B ratio is approximately 28.74% higher. Relative to its 5-year average P/B ratio of 3.76, the current P/B ratio is about 0.53% higher. Amylyx Pharmaceuticals Inc (AMLX) has a Forward Free Cash Flow (FCF) yield of approximately -15.21%. Compared to its 3-year average FCF yield of -19.75%, the current FCF yield is approximately -22.99% lower. Relative to its 5-year average FCF yield of -17.23% , the current FCF yield is about -11.75% lower.
P/B
Median3y
2.93
Median5y
3.76
FCF Yield
Median3y
-19.75
Median5y
-17.23
Competitors Valuation Multiple
AI Analysis for AMLX
The average P/S ratio for AMLX competitors is 2104.36, providing a benchmark for relative valuation. Amylyx Pharmaceuticals Inc Corp (AMLX.O) exhibits a P/S ratio of 12059.03, which is 473.05% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for AMLX
1Y
3Y
5Y
Market capitalization of AMLX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AMLX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AMLX currently overvalued or undervalued?
Amylyx Pharmaceuticals Inc (AMLX) is now in the Fair zone, suggesting that its current forward PS ratio of 12059.03 is considered Fairly compared with the five-year average of 0.79. The fair price of Amylyx Pharmaceuticals Inc (AMLX) is between to according to relative valuation methord.
What is Amylyx Pharmaceuticals Inc (AMLX) fair value?
AMLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Amylyx Pharmaceuticals Inc (AMLX) is between to according to relative valuation methord.
How does AMLX's valuation metrics compare to the industry average?
The average P/S ratio for AMLX's competitors is 2104.36, providing a benchmark for relative valuation. Amylyx Pharmaceuticals Inc Corp (AMLX) exhibits a P/S ratio of 12059.03, which is 473.05% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
What is the current P/B ratio for Amylyx Pharmaceuticals Inc (AMLX) as of Jan 09 2026?
As of Jan 09 2026, Amylyx Pharmaceuticals Inc (AMLX) has a P/B ratio of 3.78. This indicates that the market values AMLX at 3.78 times its book value.
What is the current FCF Yield for Amylyx Pharmaceuticals Inc (AMLX) as of Jan 09 2026?
As of Jan 09 2026, Amylyx Pharmaceuticals Inc (AMLX) has a FCF Yield of -15.21%. This means that for every dollar of Amylyx Pharmaceuticals Inc’s market capitalization, the company generates -15.21 cents in free cash flow.
What is the current Forward P/E ratio for Amylyx Pharmaceuticals Inc (AMLX) as of Jan 09 2026?
As of Jan 09 2026, Amylyx Pharmaceuticals Inc (AMLX) has a Forward P/E ratio of -8.87. This means the market is willing to pay $-8.87 for every dollar of Amylyx Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Amylyx Pharmaceuticals Inc (AMLX) as of Jan 09 2026?
As of Jan 09 2026, Amylyx Pharmaceuticals Inc (AMLX) has a Forward P/S ratio of 12059.03. This means the market is valuing AMLX at $12059.03 for every dollar of expected revenue over the next 12 months.